Phase 3, randomized, double-blind study of adjuvant immunotherapy with Relatlimab and Nivolumab in fixed-dose combination versus Nivolumab monotherapy in patients with stage III-IV melanoma after complete resection
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)
- Phase: III
- Execution start: 10/12/2021
- End of execution: 30/12/2028
- IP: JAVIER VALDIVIA BAUTISTA